Navigation Links
Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility

OXFORD, England, 20 June 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology company, announces that it has been awarded a grant of £400,000 by the Welsh Development Agency (”WDA”) under the SMARTCymru scheme. The grant, which runs for 12 months, will support the research and development work undertaken at VASTox’s Aberystwyth facility and provides recognition of the unique skills and expertise of its scientists based there.

The research facility in Wales forms a key part of VASTox's world-leading carbohydrate chemistry technology platform, which also comprises its specialist carbohydrate chemistry subsidiary, Dextra Laboratories, based in Reading. The research at Aberystwyth identifies naturally occurring biologically-active carbohydrate compounds with which VASTox has built a library of unique drug-like molecules. This library is expected to provide the Company with opportunities to create new drug programmes across a broad range of therapeutic areas thereby fuelling its drug pipeline.

Steven Lee, PhD, CEO of VASTox added: "VASTox seeks to find different sources of funding to strengthen the business and the award of this sizeable grant by the WDA is illustrative of this. The grant will support both the infrastructure and R&D undertaken at our Aberystwyth site, which is an integral part of our world-leading carbohydrate chemistry technology platform and commercial offering."

- ends -

For more information please contact:

VASTox Steven Lee, PhD, Chief Executive Officer Darren Millington ACMA, Chief Financial Officer Tel: +44 (0)1235 443951

Citigate Dewe Rogerson Mark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571 Evolution Securities Tim Worlledge / Bobbie Hilliam / Neil Elliot Tel: +44 (0)207 7071 4300

About SMARTCymru

SMARTCymru is a research and development (R&D) scheme to assist new product a nd process development. It is a comprehensive, pan Wales programme, from the Welsh Assembly Government that provides easy access to funding and a unique range of skills and expertise. SMARTCymru has been developed in consultation with industry, with the specific aim of encouraging and supporting innovators to carry out R&D that has real commercial potential. Support is available for all phases of the development life-cycle, from feasibility to exploitation. It is open to all innovators who aim to create and exploit technologically innovative products and processes, based in Wales.

www.wda.co.uk/smartcymru

About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in both medicinal and carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 - s ymbol: VOX

Further information about the company is available at www.vastox.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.

Mark Swallow, Ph.D. Citigate Dewe Rogerson

+44 (0)20 7282 2948 (direct) +44 (0)7903 737703 (mobile) +44 (0)20 7638 9571 (switchboard) +44 (0)20 7282 2811 (fax) 3 London Wall Buildings London Wall London EC2M 5SY UK www.citigatedr.co.uk/pharma_biotech.html


'"/>




Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
3. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
4. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
5. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. President Bush Ignores Americas Plea for Support of Stem Cell Research
8. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
11. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... February 20, 2017 The ... anticipated to reach USD 1.4 billion by 2022, ... Research, Inc. Constant evaluation of various techniques by ... to drive growth in this market. Moreover, shunt ... of novel and improved shunts in order to ...
(Date:2/20/2017)... COTTAGE, New York , February 20, 2017 /PRNewswire/ ... a regularized absorption of calcium and phosphorous minerals in ... role of vitamin D ingredients in maintaining a healthy ... or medicines containing vitamin D ingredients is growing in ... the advantage of consuming vitamin D ingredients for treatment ...
(Date:2/19/2017)... --  AC Group Inc. , a leading company, specializing ... the PMS/EHR healthcare marketplace, will exhibit the 7 Stages ... in this ecosystem at HIMSS,17. ... over 200 ACOs, compared and analyzed an ACO,s needs ... are providing different pieces of Population Health technologies designed ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 2017 , ... Chuck E. Cheese’s® and Center for Autism and Related Disorders ... E. Cheese’s locations throughout New England, New York and New Jersey to provide children ... fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After a ...
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/17/2017)... ... , ... Smiles by Seese is a comprehensive family dental practice ... the practice as a skilled and highly credentialed dentist who is qualified to perform ... of all ages with excellence in general, restorative, and cosmetic dentistry . Their ...
(Date:2/17/2017)... (PRWEB) , ... February 17, ... ... Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — ... are the critical reimbursement questions manufacturers should be asking before selecting an ...
Breaking Medicine News(10 mins):